Metabolic Score for Insulin Resistance (METS-IR) and Circulating Cytokines in Older Persons: The Role of Gender and Body Mass Index.
aging
gender
inflammation
insulin
metabolism
obesity
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
07 Aug 2022
07 Aug 2022
Historique:
received:
13
07
2022
revised:
03
08
2022
accepted:
05
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Inflammation, along with aging processes, contributes to the development of insulin resistance (IR), but the roles of different inflammatory and other cytokines in this process remain unclear. Thus, we aimed to analyze the association between several plasma cytokines with IR as evaluated by the metabolic score for insulin resistance, METS-IR. We measured the plasma concentrations of thirty cytokines from a cohort of older persons and analyzed their role as independent factors for IR. We used regression analyses adjusted for known IR-associated factors (including age, gender, cholesterol levels, and BMI) to find the determinants of IR. The study evaluated 132 subjects, mostly women (82F/50M), slightly overweight, and with a mean age of 78.5 ± 6.5 years. In the overall population, IL-15 significantly and negatively correlates with METS-IR (r = -0.183, Our results indicate the association between cytokines and IR has to be interpreted in a gender-specific manner. In women, EGF, Eotaxin, and MCP-1 circulating levels are associated with METS-IR being BMI a significant mediator. Understanding the role of gender in the relationship between cytokines and IR will help to define individualized preventive and treatment interventions to reduce the risk of age-related metabolic disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation, along with aging processes, contributes to the development of insulin resistance (IR), but the roles of different inflammatory and other cytokines in this process remain unclear. Thus, we aimed to analyze the association between several plasma cytokines with IR as evaluated by the metabolic score for insulin resistance, METS-IR.
METHODS
METHODS
We measured the plasma concentrations of thirty cytokines from a cohort of older persons and analyzed their role as independent factors for IR. We used regression analyses adjusted for known IR-associated factors (including age, gender, cholesterol levels, and BMI) to find the determinants of IR.
RESULTS
RESULTS
The study evaluated 132 subjects, mostly women (82F/50M), slightly overweight, and with a mean age of 78.5 ± 6.5 years. In the overall population, IL-15 significantly and negatively correlates with METS-IR (r = -0.183,
CONCLUSIONS
CONCLUSIONS
Our results indicate the association between cytokines and IR has to be interpreted in a gender-specific manner. In women, EGF, Eotaxin, and MCP-1 circulating levels are associated with METS-IR being BMI a significant mediator. Understanding the role of gender in the relationship between cytokines and IR will help to define individualized preventive and treatment interventions to reduce the risk of age-related metabolic disorders.
Identifiants
pubmed: 35956404
pii: nu14153228
doi: 10.3390/nu14153228
pmc: PMC9370138
pii:
doi:
Substances chimiques
Cytokines
0
Interleukin-15
0
Epidermal Growth Factor
62229-50-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Diabetes. 2005 Apr;54(4):917-27
pubmed: 15793228
Evid Based Complement Alternat Med. 2021 Oct 29;2021:7118464
pubmed: 34745297
Diabetes. 2005 Dec;54 Suppl 2:S11-7
pubmed: 16306328
Nat Rev Endocrinol. 2012 Apr 03;8(8):457-65
pubmed: 22473333
Am J Physiol. 1993 Aug;265(2 Pt 1):E323-31
pubmed: 8103633
J Gerontol A Biol Sci Med Sci. 2019 Oct 4;74(11):1709-1715
pubmed: 30590424
Cent Eur J Immunol. 2020;45(4):461-468
pubmed: 33658893
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
Diabetes Obes Metab. 2012 Feb;14(2):190-3
pubmed: 21906226
J Clin Invest. 2006 Jun;116(6):1494-505
pubmed: 16691291
Front Endocrinol (Lausanne). 2019 Oct 30;10:703
pubmed: 31736870
Sci Rep. 2018 Feb 9;8(1):2767
pubmed: 29426925
Am J Clin Nutr. 2009 May;89(5):1307-14
pubmed: 19297456
Immunol Allergy Clin North Am. 2003 Feb;23(1):15-39
pubmed: 12645876
Endocr Metab Immune Disord Drug Targets. 2011 Mar;11(1):23-31
pubmed: 21348821
J Diabetes Res. 2017;2017:9502643
pubmed: 28812029
Trends Immunol. 2004 Jan;25(1):4-7
pubmed: 14698276
PLoS One. 2015 Mar 17;10(3):e0121971
pubmed: 25781614
Nutr Diabetes. 2021 Jun 7;11(1):15
pubmed: 34099626
Diabetologia. 2012 Dec;55(12):3350-8
pubmed: 22983634
Int Immunopharmacol. 2021 Dec;101(Pt B):107598
pubmed: 34233864
Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6
pubmed: 15142631
Obesity (Silver Spring). 2010 Aug;18(8):1601-7
pubmed: 20019685
J Clin Endocrinol Metab. 2008 Nov;93(11):4486-93
pubmed: 18697873
Front Cardiovasc Med. 2018 Feb 22;5:12
pubmed: 29564335
PLoS One. 2018 Dec 17;13(12):e0208038
pubmed: 30557342
Cytokine Growth Factor Rev. 2002 Dec;13(6):429-39
pubmed: 12401478
J Clin Endocrinol Metab. 2006 Jan;91(1):256-61
pubmed: 16263831
J Biomed Sci. 2016 Dec 3;23(1):87
pubmed: 27912756
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Diabetes. 2012 Jun;61(6):1315-22
pubmed: 22618766
Eur J Endocrinol. 2018 May;178(5):533-544
pubmed: 29535168
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
Inflammation. 2022 Feb;45(1):31-44
pubmed: 34536157
Diabetes Res Clin Pract. 2011 Oct;94(1):146-55
pubmed: 21824674
Curr Opin Hematol. 2001 May;8(3):131-6
pubmed: 11303144
J Neuroendocrinol. 2016 Nov;28(11):
pubmed: 27632792